Insiders, R&D

The BCMA frenzy: Tracking the 37 drugs around the world racing to overtake bluebird bio and Celgene

Bluebird bio’s bb2121 is sitting on top of a volcano of clinical rivalry aimed at BCMA.

Currently in an advanced clinical trial, Nick Leschly’s biotech is in a vulnerable lead position as they hunt first mover advantage. In cancer R&D, developers can move fast. And coming in a close second can still position you for success, as Merck found out with PD-1 and Kite/Gilead proved with CAR-T.

But there’s no end of appetite among developers willing to come in much, much later. A whole new group is coming out of China that could end up commoditizing each of these fields.

To get a better lay of the global landscape here, I asked Jun Tang at the Cancer Research Institute — who’s been running a fascinating effort to stay on top of the full explosion of I/O activity — to scrape the database to see what’s actually in the clinic. He discovered that there are 38 clinical-stage BCMA-targeted agents in development — 27 CAR-Ts, 6 CD-3 targeted bispecifics, 3 antibody-drug conjugates and a single novel cell therapy and monoclonal antibody.

You can see the full chart below.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->